LAG3 and neoplasm: The combination of antibodies (Abs) blocking PD-1 and LAG-3 is also of great interest due to their expression on tumor infiltrating lymphocytes (TILs), thereby restricting T-cell responses to the tumor microenvironment (TME), and which might lead to a favorable safety profile.